Finally, we discuss emerging strategies on the horizon, including better patient selection and novel drug combinations, that hold promise for overcoming existing limitations and advancing the field toward more effective and durable therapeutic solutions for patients with KRAS G12C-mutated cancers. Here, KRAS is linked to cancer.